The Impact of the Innate Immune System in Alveolar Soft Part Sarcoma

Simple item page
dc.contributor.advisorSenger, Donna
dc.contributor.advisorChan, Jennifer
dc.contributor.authorPhilippot, Alexis Marie
dc.contributor.committeememberMonument, Michael
dc.contributor.committeememberNarendran, Aru
dc.date2023-02
dc.date.accessioned2022-11-17T16:31:31Z
dc.date.available2022-11-17T16:31:31Z
dc.date.issued2022-11-15
dc.description.abstractAlveolar Soft Part Sarcoma (ASPS) is a rare pediatric malignancy which has characteristically poor clinical outcomes, largely due to a complete lack of chemotherapeutic treatment options, and a high likelihood of metastasis. Further, a lack of pre-clinical models has hampered progression in the understanding of the tumor’s biology and resistance to chemotherapies since it was originally described in 1952. After being in the privileged position of receiving ASPS tumor tissue from the lung metastasis of a 14-year-old female, the Senger laboratory successfully established an ASPS patient derived xenograft (PDX) model and corresponding cell line. Recent literature has suggested that the tumor microenvironment (TME) is implicated in the tumor progression of multiple soft tissue sarcomas, including ASPS; specifically, macrophage have been described as a prominent prognostic marker. Therefore, using this PDX model, we characterized the innate immune component of the TME with respect to the cell populations and cytokines secreted by both the tumor cells and stroma. Unsurprisingly, the PDX tumors were abundant in pro-tumor macrophage and pro-inflammatory cytokines. As data generated by the Senger laboratory had established the susceptibility of ASPS cells to proteasome inhibitor carfilzomib, carfilzomib was also evaluated for its anti-tumor implications on both the tumor cells and the innate immune microenvironment. After observing a number of anti-tumor changes to the macrophage within the TME following carfilzomib treatment, this chemotherapeutic significantly decreased tumor burden in ASPS PDX bearing mice suggesting the TME may be the Achille’s heel to this chemotherapy resistant sarcoma.en_US
dc.identifier.citationPhilippot, A. M. (2022). The impact of the innate immune system in Alveolar Soft Part Sarcoma (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca.en_US
dc.identifier.urihttp://hdl.handle.net/1880/115504
dc.identifier.urihttps://dx.doi.org/10.11575/PRISM/40471
dc.language.isoengen_US
dc.publisher.facultyCumming School of Medicineen_US
dc.publisher.institutionUniversity of Calgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.en_US
dc.subjectSarcomaen_US
dc.subjectTumor Microenvironmenten_US
dc.subjectMacrophageen_US
dc.subjectProteasome Inhibitorsen_US
dc.subject.classificationEducation--Sciencesen_US
dc.subject.classificationImmunologyen_US
dc.subject.classificationOncologyen_US
dc.titleThe Impact of the Innate Immune System in Alveolar Soft Part Sarcomaen_US
dc.typemaster thesisen_US
thesis.degree.disciplineMedicine – Medical Sciencesen_US
thesis.degree.grantorUniversity of Calgaryen_US
thesis.degree.nameMaster of Science (MSc)en_US
ucalgary.item.requestcopytrueen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ucalgary_2022_philippot_alexis.pdf
Size:
18.91 MB
Format:
Adobe Portable Document Format
Description:
Main article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.62 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Theses and Dissertations